Insights from 2023 ASH Annual Meeting

 

Insights from 2023 ASH Annual Meeting
Avatar

ASH 2023 Insights: "ViPOR Trial - Multi-Targeted Therapy With Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide R/R DLBCL"

By Insights from 2023 ASH Annual Meeting FEATURING Christopher J. Melani
By Insights from 2023 ASH Annual Meeting FEATURING Christopher J. Melani
51 views
December 19, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray

Featured Video

24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi
Lymphoma
06:43
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of MCL - Highlights & Key Takea…

Feat. V. Yazbeck
11:40
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "The European MCL Network R2 Elderly Trial -…

Feat. V. Ribrag
08:29
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "CAR T-Cell Therapy in Aggressive Lymphomas …

Feat. A. Sureda
05:12
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Results From ELM-2, a Ph 2 Study of Odronex…

Feat. J. C. Villasboas
08:30
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "PD-1 Blockade Before AutoSCT in R/R Classic…

Feat. S. Desai
11:11
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Ibrutinib and Venetoclax in Symptomatic, Tr…

Feat. J. Castillo
09:27
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Ph2 EpiRCHOP Study - Tazemetostat With R-CH…

Feat. C. Sarkozy
09:10
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Acalabrutinib Added to Lenalidomide & R…

Feat. P. Strati
06:00
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Effectiveness of CIT and Novel Therapies in…

Feat. L. Nastoupil
09:05
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Time-Limited Exposure to a ROR1-Targeting B…

Feat. P. Jasani
06:09
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Outcomes of Pts With Richter's Transfo…

Feat. A. Kittai
05:45
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Anti-CD19 CAR T-Cell Therapy for Richter&#x…

Feat. A. Kittai
13:38
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "S1826 Trial - Nivo-AVD Compared to Brentuxi…

Feat. S. Castellino
02:27
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Efficacy of Mosunetuzumab Monotherapy in Pa…

Feat. C. Cheah
02:26
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Obinutuzumab, Lenalidomide, and Venetoclax …

Feat. C. Cheah
10:19
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Final Analysis of the ELM-2 Study - Odronex…

Feat. S. Ayyappan
10:57
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Mosunetuzumab + Polatuzumab Vedotin in Pts …

Feat. E. Budde
13:46
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Smart Stop Trial - Lenalidomide, Tafasitama…

Feat. J. Westin
30:24
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Treatment of Older Patients With HL in the …

Feat. A. Evens
10:58
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "ViPOR Trial - Multi-Targeted Therapy With V…

Feat. C. Melani
11:05
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Alliance A051301/BMT-CTN 1201 Study - Ibrut…

Feat. C. Andreadis
06:30
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Pirtobrutinib in R/R FL - Results From the …

Feat. N. Shah
11:11
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prognostic Utility of MRD After Curative In…

Feat. B. Sworder
08:59
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "SWOG S1826 Trial - Nivo-AVD vs. Bv-AVD in O…

Feat. S. Rutherford
11:43
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Selection of Bispecific Antibody Therapies …

Feat. M. Kamdar
16:09
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Addition of Inotuzumab Ozogamicin to the Co…

Feat. I. Khouri
10:21
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "EOT Response Assessment After 1L Tx For Agg…

Feat. M. Roschewski
13:06
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "ECOG-ACRIN E4412 Study of Ipi, Nivo, and Br…

Feat. C. Diefenbach
18:05
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Optimal Management of R/R cHL - Post-Brentu…

Feat. N. Grover
09:56
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Limited Duration Loncastuximab Tesirine Wit…

Feat. J. Pablo Alderuccio
11:42
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Impact of Large Cells and Ki-67% on Outcome…

Feat. N. Epperla
04:34
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "Highlights and Key Takeaways in MCL"

Feat. P. Jain
05:10
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Efficacy of Double Step-Up Dosing of AZD048…

Feat. S. Gaballa
05:41
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Acalabrutinib With Rituximab as 1L Therapy …

Feat. P. Jain
04:56
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Immune Reconstitution and Infection Pattern…

Feat. M. Melody
10:28
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Multicenter Study of MCL Outcomes Following…

Feat. Y. Wang